Barclays’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Barclays’s Portfolio AVNR Stock Details AVNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,085,179	Closed	-$33.4M	–	7542
2014 Q4	$33.4M	Buy	2,085,179 +967,306	+87%	+$13.6M	0.03%	513
2014 Q3	$12.3M	Buy	1,117,873 +437,288	+64%	+$2.99M	0.01%	1032
2014 Q2	$3.4M	Sell	680,585 -31,351	-4%	-$144K	﹤0.01%	2102
2014 Q1	$2.14M	Buy	711,936 +241,309	+51%	+$920K	﹤0.01%	2485
2013 Q4	$1.41M	Buy	470,627 +408,767	+661%	+$1.69M	﹤0.01%	3024
2013 Q3	$248K	Sell	61,860 -547,428	-90%	-$2.59M	﹤0.01%	4830
2013 Q2	$2.8M	Buy	+609,288	New	+$2.09M	﹤0.01%	2165

Barclays's AVNR Position: Q1 2015 in Review

Barclays sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 2,085,179 shares — an estimated $33.4M sold.

Barclays first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $33.4M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

Barclays reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
Barclays sold 2,085,179 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $33.4M.
Barclays first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
Barclays's AVANIR PHARMACEUTICALS, INC CL A position peaked at $33.4M in Q4 2014.
0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Barclays's 13F filing for Q1 2015, filed 14 May 2015.